Collegium Pharmaceutical, Inc. Total Shareholder Rtn Amt
Collegium Pharmaceutical, Inc. (COLL) reported Total Shareholder Rtn Amt of $224.98 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-07.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-07
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $224.98 DEF 14A · filed 2026-04-07 |
| 2024-12-31 | $139.21 DEF 14A · filed 2026-04-07 |
| 2023-12-31 | $149.56 DEF 14A · filed 2026-04-07 |
| 2022-12-31 | $112.73 DEF 14A · filed 2026-04-07 |
| 2021-12-31 | $90.77 DEF 14A · filed 2026-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |